Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

Lupus - Tập 9 Số 9 - Trang 664-671 - 2000
Mattias Collin1, Gunnar Sturfelt2, L Truedsson3, Jonas Blomberg4, Gunnar V. Alm, Helena Vallin5, L Rönnblom6
1Department Of Rheumatology, University Hospital, Lund, Sweden
2Department of Rheumatology, University Hospital, S-221 85 Lund, Sweden;
3Department of Clinical Microbiology, University Hospital, Lund, Sweden
4Section of Virology, Department of Clinical Microbiology, University Hospital, Uppsala, Sweden
5Section of Immunology, Department of Veterinary Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden
6Section of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Tóm tắt

The objective was to investigate the relation between serum levels of interferon-α (IFN-α), the activity of an endogenous IFN-a inducing factor (SLE-IIF), clinical and immunological disease activity as well as serum levels of antiretroviral antibodies in SLE. Serum levels of IFN-α were measured in serial sera from 30 patients sampled at different stages of disease activity (SLEDAI score). The SLE-IIF activity was measured by its ability to induce IFN-α production in cultures of normal peripheral blood mononuclear cells. Both serum IFN-α and SLE-IIF increased markedly at flare in serially followed patients. The SLEDAI score, levels of anti-dsDNA antibodies and IL-10 correlated positively, and complement components Clq, C3 and leukocytes correlated inversely with serum concentrations of IFN-α. The extent of multiple organ involvement correlated with serum IFN-α. No relation between concentrations of retroviral peptide binding antibodies and IFN-α or SLE-IIF activity was found. The close relationship between disease activity in SLE patients and IFN-α serum levels suggests that activation of the type I IFN system might be of importance in the disease process.

Từ khóa


Tài liệu tham khảo

10.1111/j.1699-0463.1995.tb01092.x

10.1006/smim.1998.0138

De Maeyer E, 1988, Interferons and Other Regulatory Cytokines

10.1084/jem.189.3.521

10.1084/jem.185.5.825

10.1016/S0165-2427(98)00088-9

10.1002/art.1780250717

10.1136/ard.48.10.861

Kim T, 1987, Clin Exp Immunol, 70, 562

10.1136/ard.44.2.104

10.1002/art.1780270523

10.1126/science.6176024

10.1111/j.1365-2133.1987.tb04111.x

10.1002/art.1780280605

Strannegaård O, 1982, Clin Exp Immunol, 50, 246

10.1046/j.1365-2249.1999.00772.x

10.1007/BF00269199

10.1002/art.1780330414

10.1002/art.1780250407

10.1111/j.1365-2796.1990.tb00144.x

10.7326/0003-4819-115-3-178

10.1016/S0022-3476(05)80913-8

10.1002/art.1780360224

10.1177/096120339400300605

10.1093/qjmed/91.6.393

Vallin H, 1999, J Immunol, 163, 6306, 10.4049/jimmunol.163.11.6306

10.1006/jaut.1998.0215

10.1046/j.1365-3083.1996.d01-289.x

10.1002/art.1780370109

10.1002/art.1780391007

10.1002/art.1780350606

Gladman DD, 2000, J Rheumatol, 27, 377

10.1093/rheumatology/36.12.1283

Johnson U, 1983, Acta Pathol Microbiol Immunol Scand, 91, 147

10.1097/00005792-199207000-00004

Tan EM, 1966, J Immunol, 96, 464, 10.4049/jimmunol.96.3.464

10.1203/00006450-199001000-00002

Chakrabarti D, 1996, J Immunol, 157, 522, 10.4049/jimmunol.157.2.522

10.1182/blood.V87.11.4731.bloodjournal87114731

10.1084/jem.181.3.839

Payvandi F, 1998, J Immunol, 160, 5861, 10.4049/jimmunol.160.12.5861

10.1006/jaut.1999.0300

10.3109/03009748509165503

Korb LC, 1997, J Immunol, 158, 4525, 10.4049/jimmunol.158.10.4525

10.1111/j.1600-065X.1996.tb00914.x

10.1002/jlb.61.6.654

10.1089/jir.1990.10.621

Simons PJ, 1994, Cancer Immunol Immunother, 38, 178

Kirou KA, 1999, Arthritis Rheum, 42, S308

Thông tin
Thông tin xuất bản

Lupus

Tập 9 Số 9

664-671

Thông tin tác giả